Whalesbook
FDA Approves Lupin's Famotidine Injection
Lupin Pharmaceuticals announced on May 13, 2026, that the U.S. Food and Drug Administration (FDA) approved its famotidine injection USP, 20 mg/2 mL (10 mg/mL) single-dose vials. This product is bioequivalent to Merck Sharp & Dohme's Pepcid Injection. It is intended for intravenous use in hospitalized patients who have conditions causing excessive stomach acid production or have intractable ulcers. It also serves as an option for patients unable to take oral medication. Manufactured at Lupin's facility in Nagpur, the injectable is expected to generate approximately $8.7 million in annual U.S. sales. This approval supports Lupin's strategic shift toward higher-margin, complex generics and injectables, aiming to reduce reliance on the highly competitive oral generics market.
Strong Q4 Results Mask Stock Dip
The famotidine approval came shortly after Lupin reported strong financial results for its fourth quarter and full fiscal year 2026. For the January-March quarter, the company's consolidated net profit soared by nearly 97% year-over-year to approximately ₹1,460 crore. This growth was driven by a strong performance in its U.S. generics business and broad-based global revenue increases. Quarterly revenue from operations jumped 31.9% to ₹7,475 crore. For the full fiscal year 2026, net profit increased by 62.5% to ₹5,333 crore, with revenue up 23.1% to ₹27,958 crore. Despite these strong figures, Lupin's stock closed down 1.36% on May 13, 2026, at ₹2,215.45. This subdued reaction echoed past instances where approvals, such as for Dapagliflozin tablets in April 2026, led to only minor stock movements.
U.S. Market Faces Pressure, Lupin Pursues Complex Generics
Lupin operates within the Indian pharmaceutical sector, which is forecast to grow steadily by 7-9% in FY2026, supported by strong domestic demand and growing export markets. However, the U.S. generics market, a key revenue source for Indian companies, faces moderated growth. It is expected to slow to 3-5% year-over-year, down from nearly 10% in FY2025, due to increasing pricing pressures and competition. The overall U.S. generic drug market is projected to reach $130-$150 billion by 2026, growing at a compound annual growth rate (CAGR) of around 3-5%.
Lupin's strategy to focus on complex generics and injectables, like the new famotidine injection, is crucial. This market segment generally has fewer competitors and offers more stable revenue streams than the price-sensitive oral generics. Competitors like Sun Pharma, Dr. Reddy's, Cipla, and Zydus are actively competing for market share in both the U.S. and global markets.
Investor Concerns Remain Over U.S. Market Challenges
Despite the positive developments, risks remain for Lupin. The U.S. generics market is known for intense pricing pressure and regulatory scrutiny, which can limit the profitability of new product launches, even in the injectable segment. The estimated $8.7 million in annual sales for the famotidine injection, while a positive addition, is relatively modest within Lupin's overall revenue picture. Furthermore, while the broader outlook for Indian pharmaceutical exports is strong, the U.S. market presents challenges, including potential trade investigations and a general growth slowdown. Some analysts suggest caution, with a few reports indicating 'Hold' ratings or price targets that acknowledge potential downside, with one scenario suggesting a target price of ₹1,600.
Analysts See Growth Potential Despite Headwinds
Analysts generally maintain a constructive outlook on Lupin, with a consensus rating of 'Moderate Buy'. The average 12-month price target ranges from ₹2,400 to ₹2,700. The company's ongoing transition towards complex generics, biosimilars, and injectables is viewed as a key driver for future growth and improved profit margins. Management highlights the company's resilience and strategic investments in technology and operations. Lupin's success in securing regulatory approvals across different therapeutic areas and expanding its global reach, especially in high-value markets, will be vital for navigating the competitive landscape and delivering sustained shareholder value.